BioSpace News Archive

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD).

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2019.

Masimo (NASDAQ: MASI) today announced its financial results for the third quarter ended September 28, 2019.

Innoviva, Inc. (NASDAQ: INVA) (the “Company”) today reported financial results for the third quarter ended September 30, 2019.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

QIAGEN N.V. announced results of operations for the third quarter and first nine months of 2019..

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that its management is scheduled to participate in the Stephens Investor Conference on Wednesday, November 13, 2019, at 2:30 p.m. CST in Nashville, TN..

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the third quarter ended September 29, 2019.